Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

Table 1 Effect of SGLT2 inhibitors on clinical outcomes in adults with diabetic kidney disease

Outcome	No. studies	No. events	Sample size	HR (95% CI)	I², %	P_{Heterogeneity}	P_{Egger test}
MACE	6	2271	21,913	0.83 (0.75–0.93)	33.8	0.183	0.287
Kidney composite	5	1197	21,195	0.66 (0.58–0.75)	0.0	0.949	0.513
HHF	6	1219	22,346	0.62 (0.55–0.71)	0.0	0.844	0.267
Cardiovascular death	5	953	20,539	0.84 (0.74–0.96)	0.0	0.639	0.996
Fatal and nonfatal MI	5	498*	20,108	0.78 (0.67–0.92)	7.7	0.363	0.671
Fatal and nonfatal stroke	5	332*	20,108	0.76 (0.59–0.97)	41.3	0.146	0.564
All-cause mortality	5	1451	21,406	0.86 (0.77–0.96)	14.5	0.322	0.268

*The number of MI events and stroke cases from the SCORED trial were not reported in the primary trials and are not included in the table. CI indicates confidence interval; HHF hospitalization for heart failure, HR hazard ratio, I², I-squared, MACE Major Adverse Cardiovascular Events, MI myocardial infarction, SCORED Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk, SGLT2 sodium-glucose cotransporter 2; SGLT2, sodium-glucose cotransporter 2, SOLOIST-WHF Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure, VERTIS CV Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial

ISSN: 1475-2840